Related Experiment Video
Updated: Feb 4, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Biomarker-driven and molecular targeted therapies for colorectal cancers
Marta Schirripa1, Stacey A Cohen2, Francesca Battaglin1
1Division of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
Abstract:
Improved clinical selection and identification of new molecules and innovative strategies have widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and probably will be soon adopted into daily clinical practice. In the present review, the role RAS, BRAF mutations, Her2 amplification, microsatellite instability, and CpG island methylator phenotype are discussed according to their possible roles as prognostic, predictive markers, as well as possible biomarker-driven treatment options.
Insights
Biomarker-driven therapies are improving metastatic colorectal cancer treatment. This review covers key biomarkers like RAS, BRAF, Her2, and MSI, exploring their role in patient selection and targeted treatment strategies.
Area of Science:
- Oncology
- Genetics
Background:
- Metastatic colorectal cancer (mCRC) treatment has advanced with new strategies.
- Biomarker-driven therapies are crucial for personalized mCRC treatment.
Purpose of the Study:
- To review the role of key biomarkers in mCRC.
- To discuss prognostic and predictive value of biomarkers.
- To explore biomarker-driven treatment options for mCRC.
Main Methods:
- Literature review of prognostic and predictive biomarkers in mCRC.
- Analysis of RAS, BRAF mutations, Her2 amplification, microsatellite instability (MSI), and CpG island methylator phenotype (CIMP).
Main Results:
- RAS and BRAF mutations impact treatment selection.
- Her2 amplification is an emerging target.
- MSI and CIMP status influence prognosis and treatment response.
Conclusions:
- Biomarkers are essential for optimizing mCRC patient selection.
- Targeted therapies based on biomarkers are transforming mCRC care.
- Further research into novel biomarkers will enhance treatment strategies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Gene Therapy
Molecular Models
Molecular Orbital Theory II
Molecular Orbital Theory I

